Chapter/Section Purchase

1 Study Coverage
1.1 Malignant Mesothelioma Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Carboplatin
1.2.5 Gemcitabine
1.2.6 Vinorelbine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Oncology Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Malignant Mesothelioma Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Malignant Mesothelioma Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Malignant Mesothelioma Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Malignant Mesothelioma Drugs Sales by Region
2.4.1 Global Malignant Mesothelioma Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Malignant Mesothelioma Drugs by Region (2023-2028)
2.5 Global Malignant Mesothelioma Drugs Revenue by Region
2.5.1 Global Malignant Mesothelioma Drugs Revenue by Region (2017-2022)
2.5.2 Global Malignant Mesothelioma Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Malignant Mesothelioma Drugs Sales by Manufacturers
3.1.1 Global Top Malignant Mesothelioma Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Malignant Mesothelioma Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Malignant Mesothelioma Drugs in 2021
3.2 Global Malignant Mesothelioma Drugs Revenue by Manufacturers
3.2.1 Global Malignant Mesothelioma Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Drugs Revenue in 2021
3.3 Global Malignant Mesothelioma Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Malignant Mesothelioma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Malignant Mesothelioma Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Malignant Mesothelioma Drugs Sales by Type
4.1.1 Global Malignant Mesothelioma Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Malignant Mesothelioma Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Malignant Mesothelioma Drugs Sales Market Share by Type (2017-2028)
4.2 Global Malignant Mesothelioma Drugs Revenue by Type
4.2.1 Global Malignant Mesothelioma Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Malignant Mesothelioma Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Malignant Mesothelioma Drugs Price by Type
4.3.1 Global Malignant Mesothelioma Drugs Price by Type (2017-2022)
4.3.2 Global Malignant Mesothelioma Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Malignant Mesothelioma Drugs Sales by Application
5.1.1 Global Malignant Mesothelioma Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Malignant Mesothelioma Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Malignant Mesothelioma Drugs Sales Market Share by Application (2017-2028)
5.2 Global Malignant Mesothelioma Drugs Revenue by Application
5.2.1 Global Malignant Mesothelioma Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Malignant Mesothelioma Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Malignant Mesothelioma Drugs Price by Application
5.3.1 Global Malignant Mesothelioma Drugs Price by Application (2017-2022)
5.3.2 Global Malignant Mesothelioma Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Malignant Mesothelioma Drugs Market Size by Type
6.1.1 North America Malignant Mesothelioma Drugs Sales by Type (2017-2028)
6.1.2 North America Malignant Mesothelioma Drugs Revenue by Type (2017-2028)
6.2 North America Malignant Mesothelioma Drugs Market Size by Application
6.2.1 North America Malignant Mesothelioma Drugs Sales by Application (2017-2028)
6.2.2 North America Malignant Mesothelioma Drugs Revenue by Application (2017-2028)
6.3 North America Malignant Mesothelioma Drugs Market Size by Country
6.3.1 North America Malignant Mesothelioma Drugs Sales by Country (2017-2028)
6.3.2 North America Malignant Mesothelioma Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Drugs Market Size by Type
7.1.1 Europe Malignant Mesothelioma Drugs Sales by Type (2017-2028)
7.1.2 Europe Malignant Mesothelioma Drugs Revenue by Type (2017-2028)
7.2 Europe Malignant Mesothelioma Drugs Market Size by Application
7.2.1 Europe Malignant Mesothelioma Drugs Sales by Application (2017-2028)
7.2.2 Europe Malignant Mesothelioma Drugs Revenue by Application (2017-2028)
7.3 Europe Malignant Mesothelioma Drugs Market Size by Country
7.3.1 Europe Malignant Mesothelioma Drugs Sales by Country (2017-2028)
7.3.2 Europe Malignant Mesothelioma Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Malignant Mesothelioma Drugs Market Size by Type
8.1.1 Asia Pacific Malignant Mesothelioma Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Malignant Mesothelioma Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Malignant Mesothelioma Drugs Market Size by Application
8.2.1 Asia Pacific Malignant Mesothelioma Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Malignant Mesothelioma Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Malignant Mesothelioma Drugs Market Size by Region
8.3.1 Asia Pacific Malignant Mesothelioma Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Malignant Mesothelioma Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Malignant Mesothelioma Drugs Market Size by Type
9.1.1 Latin America Malignant Mesothelioma Drugs Sales by Type (2017-2028)
9.1.2 Latin America Malignant Mesothelioma Drugs Revenue by Type (2017-2028)
9.2 Latin America Malignant Mesothelioma Drugs Market Size by Application
9.2.1 Latin America Malignant Mesothelioma Drugs Sales by Application (2017-2028)
9.2.2 Latin America Malignant Mesothelioma Drugs Revenue by Application (2017-2028)
9.3 Latin America Malignant Mesothelioma Drugs Market Size by Country
9.3.1 Latin America Malignant Mesothelioma Drugs Sales by Country (2017-2028)
9.3.2 Latin America Malignant Mesothelioma Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Type
10.1.1 Middle East and Africa Malignant Mesothelioma Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Malignant Mesothelioma Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Application
10.2.1 Middle East and Africa Malignant Mesothelioma Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Malignant Mesothelioma Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country
10.3.1 Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Malignant Mesothelioma Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AstraZeneca Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Overview
11.2.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Overview
11.3.3 Roche Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Roche Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche Recent Developments
11.4 Merck
11.4.1 Merck Corporation Information
11.4.2 Merck Overview
11.4.3 Merck Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Merck Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Overview
11.5.3 Novartis Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Novartis Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sanofi Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Overview
11.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Eli Lilly Recent Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Corporation Information
11.9.2 Teva Pharmaceuticals Overview
11.9.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Teva Pharmaceuticals Recent Developments
11.10 Boehringer Ingelheim GmbH
11.10.1 Boehringer Ingelheim GmbH Corporation Information
11.10.2 Boehringer Ingelheim GmbH Overview
11.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Boehringer Ingelheim GmbH Recent Developments
11.11 Mylan
11.11.1 Mylan Corporation Information
11.11.2 Mylan Overview
11.11.3 Mylan Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Mylan Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Mylan Recent Developments
11.12 Fresenius Kabi
11.12.1 Fresenius Kabi Corporation Information
11.12.2 Fresenius Kabi Overview
11.12.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Fresenius Kabi Recent Developments
11.13 Sun Pharmaceuticals
11.13.1 Sun Pharmaceuticals Corporation Information
11.13.2 Sun Pharmaceuticals Overview
11.13.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sun Pharmaceuticals Recent Developments
11.14 Corden Pharma
11.14.1 Corden Pharma Corporation Information
11.14.2 Corden Pharma Overview
11.14.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Corden Pharma Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Corden Pharma Recent Developments
11.15 Concordia International
11.15.1 Concordia International Corporation Information
11.15.2 Concordia International Overview
11.15.3 Concordia International Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Concordia International Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Concordia International Recent Developments
11.16 Kyowa Hakko Kirin
11.16.1 Kyowa Hakko Kirin Corporation Information
11.16.2 Kyowa Hakko Kirin Overview
11.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Kyowa Hakko Kirin Recent Developments
11.17 Polaris Pharmaceuticals
11.17.1 Polaris Pharmaceuticals Corporation Information
11.17.2 Polaris Pharmaceuticals Overview
11.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Polaris Pharmaceuticals Recent Developments
11.18 MolMed
11.18.1 MolMed Corporation Information
11.18.2 MolMed Overview
11.18.3 MolMed Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 MolMed Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 MolMed Recent Developments
11.19 Ono Pharmaceutical
11.19.1 Ono Pharmaceutical Corporation Information
11.19.2 Ono Pharmaceutical Overview
11.19.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Ono Pharmaceutical Recent Developments
11.20 Nichi-Iko Pharmaceutical
11.20.1 Nichi-Iko Pharmaceutical Corporation Information
11.20.2 Nichi-Iko Pharmaceutical Overview
11.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Nichi-Iko Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Malignant Mesothelioma Drugs Industry Chain Analysis
12.2 Malignant Mesothelioma Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Malignant Mesothelioma Drugs Production Mode & Process
12.4 Malignant Mesothelioma Drugs Sales and Marketing
12.4.1 Malignant Mesothelioma Drugs Sales Channels
12.4.2 Malignant Mesothelioma Drugs Distributors
12.5 Malignant Mesothelioma Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Malignant Mesothelioma Drugs Industry Trends
13.2 Malignant Mesothelioma Drugs Market Drivers
13.3 Malignant Mesothelioma Drugs Market Challenges
13.4 Malignant Mesothelioma Drugs Market Restraints
14 Key Findings in The Global Malignant Mesothelioma Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer